Yttrium-90

Yttrium-90 (⁹⁰
Y
) is a radioactive isotope of yttrium.^[2] Yttrium-90 has found a wide range of uses in radiation therapy to treat some forms of cancer.^[3] Along with other isotopes of yttrium, it is sometimes called radioyttrium.

⁹⁰
Y
undergoes beta particles emissions/decay (β⁻ decay) to zirconium-90 with a half-life of 64.1 hours^[3] and a decay energy of 2.28 MeV with an average beta energy of 0.9336 MeV.^[4] It also produces 0.01% 1.7 MeV^[5] photons during its decay process to the 0⁺ state of ⁹⁰Zr, followed by pair production.^[6] The interaction between emitted electrons and matter can lead to the emission of Bremsstrahlung radiation.

Yttrium-90 is produced by the nuclear decay of strontium-90 which has a half-life of nearly 29 years and is a fission product of uranium used in nuclear reactors. As the strontium-90 decays, chemical high-purity separation is used to isolate the yttrium-90 before precipitation.^[7][8] Yttrium-90 is also directly produced by neutron activation of natural yttrium targets (Yttrium is mononuclidic in ⁸⁹Y) in a nuclear research reactor.

⁹⁰Y plays a significant role in the treatment of hepatocellular carcinoma (HCC), leukemia, and lymphoma, although it has the potential to treat a range of tumors.^[9] Trans-arterial radioembolization is a procedure performed by interventional radiologists, in which ⁹⁰Ymicrospheres are injected into the arteries supplying the tumor.^[10] The microspheres come in two forms: resin, in which ⁹⁰Y is bound to the surface, and glass, in which ⁹⁰Y is directly incorporated into the microsphere during production.^[11] Once injected, the microspheres become lodged in blood vessels surrounding the tumor and the resulting radiation damages the nearby tissue.^[12] The distribution of the microspheres is dependent on several factors, including catheter tip positioning, distance to branching vessels, rate of injection, properties of particles, like size and density, and variability in tumor perfusion.^[12] Radioembolization with ⁹⁰Y significantly prolongs time-to-progression (TTP) of HCC,^[13] has a tolerable adverse event profile, and improves patient quality of life more than do similar therapies.^{[14] 90}Y has also found uses in tumor diagnosis by imaging the Bremsstrahlung radiation released by the microspheres.^[15] Positron emission tomography after radioembolization is also possible.^[16]

Following treatment with ⁹⁰Y, imaging is performed to evaluate ⁹⁰Y delivery and absorption to evaluate coverage of target regions and involvement of normal tissue. This is typically performed using Bremsstrahlung imaging with single-photon emission computed tomography CT (SPECT/CT), or using ⁹⁰Y position imaging with positron emission tomography CT (PET/CT).

As ⁹⁰Y undergoes beta decay, broad spectrum bremsstrahlung radiation is emitted and is detectable with standard gamma cameras or SPECT.^[17][18] These modalities provide information about radioactive uptake of ⁹⁰Y, however, there is poor spatial information.^[17][18] Consequently, it is challenging to delineate anatomy and thereby evaluate tumor and normal tissue uptake. This led to the development of SPECT/CT, which combines the functional information of SPECT with the spatial information of CT to allow for more accurate ⁹⁰Y localization.^[17][18]

PET/CT and PET/MRI have superior spatial resolution compared to SPECT/CT because PET detects positron pairs produced from the decay of emitted positrons, negating the requirement for a physical collimator.^[17][18] This allows for better assessment of microsphere distribution and dose absorption. However, both PET/CT and PET/MRI are less widely available and more costly.^[17][18]

• Radionuclide therapy
• Selective internal radiation therapy

• CID {{{1}}} from PubChem